U.S. Markets closed
  • S&P Futures

    3,649.75
    -10.75 (-0.29%)
     
  • Dow Futures

    29,670.00
    -134.00 (-0.45%)
     
  • Nasdaq Futures

    12,427.25
    -25.00 (-0.20%)
     
  • Russell 2000 Futures

    1,831.00
    -4.50 (-0.25%)
     
  • Crude Oil

    44.11
    -0.44 (-0.99%)
     
  • Gold

    1,813.00
    -5.90 (-0.32%)
     
  • Silver

    23.83
    -0.26 (-1.06%)
     
  • EUR/USD

    1.2086
    +0.0007 (+0.0604%)
     
  • 10-Yr Bond

    0.9340
    +0.0900 (+10.66%)
     
  • Vix

    20.77
    +0.20 (+0.97%)
     
  • GBP/USD

    1.3418
    -0.0005 (-0.0362%)
     
  • USD/JPY

    104.3580
    +0.0420 (+0.0403%)
     
  • BTC-USD

    18,424.88
    -271.29 (-1.45%)
     
  • CMC Crypto 200

    361.92
    -17.94 (-4.72%)
     
  • FTSE 100

    6,384.73
    +118.54 (+1.89%)
     
  • Nikkei 225

    26,804.10
    +16.56 (+0.06%)
     

What Kind Of Shareholders Hold The Majority In Checkpoint Therapeutics, Inc.'s (NASDAQ:CKPT) Shares?

Simply Wall St
·5 min read

Every investor in Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) should be aware of the most powerful shareholder groups. Large companies usually have institutions as shareholders, and we usually see insiders owning shares in smaller companies. I generally like to see some degree of insider ownership, even if only a little. As Nassim Nicholas Taleb said, 'Don’t tell me what you think, tell me what you have in your portfolio.

With a market capitalization of US$164m, Checkpoint Therapeutics is a small cap stock, so it might not be well known by many institutional investors. In the chart below, we can see that institutions are noticeable on the share registry. We can zoom in on the different ownership groups, to learn more about Checkpoint Therapeutics.

Check out our latest analysis for Checkpoint Therapeutics

ownership-breakdown
ownership-breakdown

What Does The Institutional Ownership Tell Us About Checkpoint Therapeutics?

Institutions typically measure themselves against a benchmark when reporting to their own investors, so they often become more enthusiastic about a stock once it's included in a major index. We would expect most companies to have some institutions on the register, especially if they are growing.

We can see that Checkpoint Therapeutics does have institutional investors; and they hold a good portion of the company's stock. This suggests some credibility amongst professional investors. But we can't rely on that fact alone since institutions make bad investments sometimes, just like everyone does. It is not uncommon to see a big share price drop if two large institutional investors try to sell out of a stock at the same time. So it is worth checking the past earnings trajectory of Checkpoint Therapeutics, (below). Of course, keep in mind that there are other factors to consider, too.

earnings-and-revenue-growth
earnings-and-revenue-growth

It looks like hedge funds own 5.3% of Checkpoint Therapeutics shares. That's interesting, because hedge funds can be quite active and activist. Many look for medium term catalysts that will drive the share price higher. The company's largest shareholder is Fortress Biotech, Inc., with ownership of 16%. The second and third largest shareholders are Heights Capital Management, Inc. and Sabby Management, LLC, with an equal amount of shares to their name at 5.3%. Additionally, the company's CEO James Oliviero directly holds 4.1% of the total shares outstanding.

On studying our ownership data, we found that 25 of the top shareholders collectively own less than 50% of the share register, implying that no single individual has a majority interest.

Researching institutional ownership is a good way to gauge and filter a stock's expected performance. The same can be achieved by studying analyst sentiments. There are plenty of analysts covering the stock, so it might be worth seeing what they are forecasting, too.

Insider Ownership Of Checkpoint Therapeutics

The definition of an insider can differ slightly between different countries, but members of the board of directors always count. Management ultimately answers to the board. However, it is not uncommon for managers to be executive board members, especially if they are a founder or the CEO.

Most consider insider ownership a positive because it can indicate the board is well aligned with other shareholders. However, on some occasions too much power is concentrated within this group.

Our most recent data indicates that insiders own some shares in Checkpoint Therapeutics, Inc.. It has a market capitalization of just US$164m, and insiders have US$9.4m worth of shares, in their own names. This shows at least some alignment, but I usually like to see larger insider holdings. You can click here to see if those insiders have been buying or selling.

General Public Ownership

The general public, mostly retail investors, hold a substantial 57% stake in Checkpoint Therapeutics, suggesting it is a fairly popular stock. With this size of ownership, retail investors can collectively play a role in decisions that affect shareholder returns, such as dividend policies and the appointment of directors. They can also exercise the power to decline an acquisition or merger that may not improve profitability.

Private Equity Ownership

With a stake of 5.3%, private equity firms could influence the Checkpoint Therapeutics board. Some might like this, because private equity are sometimes activists who hold management accountable. But other times, private equity is selling out, having taking the company public.

Public Company Ownership

Public companies currently own 16% of Checkpoint Therapeutics stock. This may be a strategic interest and the two companies may have related business interests. It could be that they have de-merged. This holding is probably worth investigating further.

Next Steps:

While it is well worth considering the different groups that own a company, there are other factors that are even more important. Consider for instance, the ever-present spectre of investment risk. We've identified 5 warning signs with Checkpoint Therapeutics (at least 2 which don't sit too well with us) , and understanding them should be part of your investment process.

If you would prefer discover what analysts are predicting in terms of future growth, do not miss this free report on analyst forecasts.

NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.

This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com.